BR0206293A - Composições de imunização e métodos de uso - Google Patents

Composições de imunização e métodos de uso

Info

Publication number
BR0206293A
BR0206293A BR0206293-3A BR0206293A BR0206293A BR 0206293 A BR0206293 A BR 0206293A BR 0206293 A BR0206293 A BR 0206293A BR 0206293 A BR0206293 A BR 0206293A
Authority
BR
Brazil
Prior art keywords
methods
compositions
present
immunization
immunization compositions
Prior art date
Application number
BR0206293-3A
Other languages
English (en)
Other versions
BR0206293B1 (pt
Inventor
Daryll A Emery
Darren E Straub
Donavan E Zammert
Gayla K Kallevig
Original Assignee
Willmar Poultry Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26947345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0206293(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Willmar Poultry Co Inc filed Critical Willmar Poultry Co Inc
Publication of BR0206293A publication Critical patent/BR0206293A/pt
Publication of BR0206293B1 publication Critical patent/BR0206293B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/827—Bacterial vaccine for fish
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçõES DE IMUNIZAçãO E MéTODOS DE USO". A presente invenção fornece composições incluindo polipeptídeos receptores de sideróforos e porinas de micróbios gram negativos, e, preferivelmente, lipopolissacarídeo em uma concentração de não mais do que cerca de 10,0 unidades de endotoxina por mililitro. A presente invenção também fornece métodos para preparar e métodos para empregar tais composições.
BRPI0206293-3A 2001-01-03 2002-01-03 “composições compreendendo polipeptídeos receptores de sideróforos e porinas de micróbio gram-negativo, bem como métodos de isolar polipeptídeos de membrana externa BR0206293B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25950401P 2001-01-03 2001-01-03
US60/259,504 2001-01-03
US26289601P 2001-01-19 2001-01-19
US60/262,896 2001-01-19
PCT/US2002/000188 WO2002053180A2 (en) 2001-01-03 2002-01-03 Immunizing compositions and methods of use

Publications (2)

Publication Number Publication Date
BR0206293A true BR0206293A (pt) 2005-10-25
BR0206293B1 BR0206293B1 (pt) 2015-01-20

Family

ID=26947345

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0206293-3A BR0206293B1 (pt) 2001-01-03 2002-01-03 “composições compreendendo polipeptídeos receptores de sideróforos e porinas de micróbio gram-negativo, bem como métodos de isolar polipeptídeos de membrana externa

Country Status (14)

Country Link
US (16) US20030036639A1 (pt)
EP (1) EP1353689B9 (pt)
AT (1) ATE322288T1 (pt)
AU (1) AU2002239820C1 (pt)
BR (1) BR0206293B1 (pt)
CA (2) CA2433561C (pt)
CY (1) CY1105563T1 (pt)
DE (1) DE60210413T2 (pt)
DK (1) DK1353689T3 (pt)
ES (1) ES2265488T3 (pt)
MX (1) MXPA03006038A (pt)
NZ (1) NZ526786A (pt)
PT (1) PT1353689E (pt)
WO (1) WO2002053180A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
CA2182976C (en) * 1994-02-09 2011-07-12 Daryll A. Emery Active immunization using a siderophore receptor protein
ES2265488T3 (es) * 2001-01-03 2007-02-16 Epitopix Llc Composiciones inmunizantes y metodos de uso.
CA2538252C (en) * 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
AU2004274977B2 (en) 2003-09-19 2011-06-23 Epitopix, Llc Campylobacter polypeptides and methods of use
US7544376B2 (en) * 2004-07-30 2009-06-09 Sartec Corporation Methods and compositions for increasing milk production in animals
CA2578041C (en) 2004-08-25 2021-03-16 Epitopix, Llc Fusobacterium polypeptides and methods of use
ES2588010T3 (es) * 2005-01-21 2016-10-28 Epitopix, Llc Polipéptidos de Yersinia spp. y métodos de uso
AU2015258239B2 (en) * 2005-02-14 2017-08-17 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
AU2012244060B2 (en) * 2005-02-14 2015-08-20 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
NZ560612A (en) * 2005-02-14 2011-01-28 Epitopix Llc Polypeptides from staphylococcus aureus and methods of use
EP3167900B1 (en) * 2006-03-29 2018-11-21 Merial Limited Vaccine against streptococci
CA2652028C (en) * 2006-05-12 2013-07-16 The United States Of America, As Represented By The Secretary Of The Nav Y Secreted campylobacter flagella coregulated proteins as immunogens
EP2344224A2 (en) * 2008-08-25 2011-07-20 Koninklijke Philips Electronics N.V. Respiratory patient interfaces
CN105582524A (zh) 2009-03-23 2016-05-18 埃皮托皮克斯有限责任公司 多肽和含有革兰氏阳性多肽的免疫组合物及使用方法
EP2484305A2 (en) * 2009-09-28 2012-08-08 Carlos Alberto Barcelo Rojas Method for palpation of the physiological-reproductive condition of the uterus
US20110129479A1 (en) * 2009-12-02 2011-06-02 Tobin Monte B Immunogen selection directed in immunoglobulin packages in plasma and colostrum and method of making and using same
CN102205117B (zh) * 2011-05-19 2013-12-18 新疆维吾尔自治区畜牧科学院兽医研究所 奶牛乳房炎金黄色葡萄球菌-大肠埃希氏菌二联多价疫苗及其制备方法
DK2794849T3 (da) * 2011-12-22 2017-11-06 Vaximm Ag Fremgangsmåde til fremstilling af svækkede salmonellastammer med højt udbytte
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
CN114099461A (zh) 2013-03-13 2022-03-01 onCOUR制药股份有限公司 用于治疗炎症的免疫修饰性颗粒
JP7222711B2 (ja) 2015-07-10 2023-02-15 エピトピックス， エルエルシー タンパク質及びｋｌｅｂｓｉｅｌｌａタンパク質を含有する免疫化組成物ならびにその使用方法
BR112018009319A8 (pt) 2015-11-09 2019-02-26 Epitopix Llc polipeptídeos de fusobacterium e métodos de uso
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10905748B2 (en) * 2018-04-16 2021-02-02 Vets Plus, Inc. Ovotransferrin treatment for the reproductive tract
BR112022018160A2 (pt) * 2020-03-24 2022-10-25 Byung Chul Ahn Método de produção de composição de soro para prevenir ou tratar doenças infecciosas relacionadas à mucosa em mamíferos jovens, composição de soro produzida por ele, e uso da mesma
KR102151962B1 (ko) * 2020-03-24 2020-09-04 안병철 어린 포유동물의 전염성 질병을 예방 또는 치료하기 위한 혈청 조성물의 제조방법, 상기 방법에 의해 제조된 혈청 조성물 및 이의 용도
EP4126019A4 (en) * 2020-05-14 2024-04-17 Zivo Bioscience Inc USE OF A TLR4 MODULATOR IN THE TREATMENT OF COCCIDIOSIS
CA3236874A1 (en) 2021-10-29 2023-05-04 Vaxxinova Us, Inc. Methods and compositions for preventing infection

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US197350A (en) * 1877-11-20 Improvement in shoes
US197869A (en) * 1877-12-04 Improvement in the manufacture of glass buttons
US4003792A (en) 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4167560A (en) * 1977-04-12 1979-09-11 Texas Vet Lab, Inc. Polyvalent shipping fever vaccine
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4530963A (en) * 1982-08-20 1985-07-23 Devoe-Holbein International, N.V. Insoluble chelating compositions
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4681761A (en) * 1985-10-24 1987-07-21 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
DE3882781T3 (de) 1987-03-24 2000-04-06 British Tech Group Impfstoff gegen Pasteurella.
US5885589A (en) * 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
FR2644346B1 (fr) 1989-03-20 1994-05-13 Rhone Merieux Vaccins contre les bacteries septicemiques, preparations d'antigenes de bacteries septicemiques, nouvelles bacteries et vecteurs pour la preparation de ces antigenes ou vaccins
US5292869A (en) 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US5141743A (en) * 1989-04-27 1992-08-25 University Technologies International, Inc. Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
WO1993021951A1 (en) * 1992-04-27 1993-11-11 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US5578314A (en) * 1992-05-29 1996-11-26 The Regents Of The University Of California Multiple layer alginate coatings of biological tissue for transplantation
US5534256A (en) * 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5830479A (en) 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
CA2182976C (en) * 1994-02-09 2011-07-12 Daryll A. Emery Active immunization using a siderophore receptor protein
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6121037A (en) 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
US6048539A (en) 1995-11-02 2000-04-11 Connaught Laboratories Limited Lactoferrin receptor protein
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6902747B1 (en) * 2000-05-03 2005-06-07 Westfaliasurge, Inc. Iodine-propylene glycol teat dip
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
ES2265488T3 (es) * 2001-01-03 2007-02-16 Epitopix Llc Composiciones inmunizantes y metodos de uso.
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
US6984503B1 (en) 2002-06-27 2006-01-10 The United States Of America As Represented By The Secretary Of The Agriculture Use of recombinant bovine CD14 in the treatment and prevention of coliform mastitis in dairy cows
AU2004274977B2 (en) * 2003-09-19 2011-06-23 Epitopix, Llc Campylobacter polypeptides and methods of use
CA2578041C (en) 2004-08-25 2021-03-16 Epitopix, Llc Fusobacterium polypeptides and methods of use
ES2588010T3 (es) 2005-01-21 2016-10-28 Epitopix, Llc Polipéptidos de Yersinia spp. y métodos de uso
NZ560612A (en) * 2005-02-14 2011-01-28 Epitopix Llc Polypeptides from staphylococcus aureus and methods of use
US7913151B1 (en) * 2006-05-26 2011-03-22 Pmc-Sierra, Inc. Forward error correction with self-synchronous scramblers
JP7222711B2 (ja) * 2015-07-10 2023-02-15 エピトピックス， エルエルシー タンパク質及びｋｌｅｂｓｉｅｌｌａタンパク質を含有する免疫化組成物ならびにその使用方法

Also Published As

Publication number Publication date
ES2265488T3 (es) 2007-02-16
US20110206733A1 (en) 2011-08-25
US7371393B2 (en) 2008-05-13
US20120195899A1 (en) 2012-08-02
DE60210413T2 (de) 2006-09-07
US20060165718A1 (en) 2006-07-27
AU2002239820B2 (en) 2007-08-23
US8637048B2 (en) 2014-01-28
US7138125B2 (en) 2006-11-21
US8282941B2 (en) 2012-10-09
EP1353689B1 (en) 2006-04-05
CA2433561A1 (en) 2002-07-11
AU2002239820C1 (en) 2008-07-10
US7341732B2 (en) 2008-03-11
EP1353689A2 (en) 2003-10-22
US7943150B2 (en) 2011-05-17
DE60210413D1 (de) 2006-05-18
US8575315B2 (en) 2013-11-05
ATE322288T1 (de) 2006-04-15
US20040265329A1 (en) 2004-12-30
NZ526786A (en) 2006-02-24
US7943151B2 (en) 2011-05-17
US20040197350A1 (en) 2004-10-07
US20030036639A1 (en) 2003-02-20
US20170087238A1 (en) 2017-03-30
US20090081236A1 (en) 2009-03-26
US8993252B2 (en) 2015-03-31
WO2002053180A3 (en) 2003-03-13
CA2708949C (en) 2016-03-08
CA2433561C (en) 2014-04-01
US20130217048A1 (en) 2013-08-22
US20090162402A1 (en) 2009-06-25
BR0206293B1 (pt) 2015-01-20
US20030211118A1 (en) 2003-11-13
CA2708949A1 (en) 2002-07-11
CY1105563T1 (el) 2010-07-28
DK1353689T3 (da) 2006-07-31
US7138124B2 (en) 2006-11-21
WO2002053180A2 (en) 2002-07-11
US20110200616A1 (en) 2011-08-18
US20120195898A1 (en) 2012-08-02
US20110200637A1 (en) 2011-08-18
US20030206922A1 (en) 2003-11-06
US7147857B2 (en) 2006-12-12
US7160549B2 (en) 2007-01-09
US8425916B2 (en) 2013-04-23
EP1353689B9 (en) 2006-06-28
US20040197869A1 (en) 2004-10-07
PT1353689E (pt) 2006-08-31
MXPA03006038A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
BR0206293A (pt) Composições de imunização e métodos de uso
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
RS51157B (sr) Baff receptor (bcma), imunoregulatorni agens
ES2120042T3 (es) Polimero de varilla rigida a base de piridobisimidazol.
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
CO5690649A2 (es) Eliminacion de agregados de alto peso molecular utilizando cromatografia de hidroxiapatita
BR9906927A (pt) Proteìnas de neisseria meningitidis
ATE279517T1 (de) Il-17 receptor
DE69732868D1 (de) Mittel gegen Juckreiz
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
EA200001039A1 (ru) Кальцилитические соединения
BR0016952A (pt) Compostos derivados de fenil-piperazina substituìdos, composição farmacêutica, uso e método
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
SE9402880D0 (sv) New peptide derivatives
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
BR0210539A (pt) Processos de seleção e uso de vacinas de vetor antiartrópode
FI963055A0 (fi) Kondensaatio- ja additiopolymeereja, jotka sisältävät N,N'-sillan sisältäviä bis(tetrametyylipiperidinyylioksi)-ryhmiä

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EPITOPIX, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/01/2015, OBSERVADAS AS CONDICOES LEGAIS.